---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-010149"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2025-03-13T23:59:59+00:00"
generated_at: "2026-05-24T21:14:04.797579+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lipocine reports near-breakeven 2024; FDA requires Phase 3 for oral brexanolone

## Summary
- Net income of ~$8,400 vs net loss of $16.4M in 2023; revenue of $11.2M from license/royalty fees.
- Cash and securities $21.6M at Dec 31, 2024, vs $22.0M at Dec 31, 2023.
- FDA meeting for LPCN 1154 requires safety/efficacy study for NDA; Phase 3 start expected Q2 2025.
- TLANDO license agreements generated $10M in 2024; Verity milestones up to $259M plus tiered royalties.
- FDA removed Boxed Warning on cardiovascular risk for testosterone products in Feb 2025.

## SEC filing metadata
- accession: 0001493152-25-010149
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2025-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000149315225010149/0001493152-25-010149-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000149315225010149/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-010149
- JSON: https://secwatch.observer/filing/0001493152-25-010149.json
- Plain text: https://secwatch.observer/filing/0001493152-25-010149.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.